Loading clinical trials...
Loading clinical trials...
A Phase Ib/II First-in-human, Multicentre, Open-label, Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effect of Intrathecal S230815 in Pediatric Participants With KCNT1-related Developmental and Epileptic Encephalopathy
Conditions
Interventions
S230815- Starting dose A
S230815- Dose B
+2 more
Locations
16
United States
Children's Hospital of Orange County
Orange, California, United States
Boston Children's Hospital
Boston, Massachusetts, United States
University of Rochester Medical Center
Rochester, New York, United States
Nationwide Children's Hospital
Columbus, Ohio, United States
The Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, United States
Children's Health Dallas
Dallas, Texas, United States
Start Date
November 24, 2025
Primary Completion Date
April 15, 2028
Completion Date
April 15, 2028
Last Updated
February 11, 2026
NCT07010471
NCT06938542
NCT05226780
NCT07396883
NCT03936777
NCT07176832
Institut de Recherches Internationales Servier
CONTACT
+33 1 55 72 60-00scientificinformation@servier.comLead Sponsor
Institut de Recherches Internationales Servier
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions